Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report)’s stock price dropped 2.5% during trading on Friday . The company traded as low as $5.02 and last traded at $5.17. 32,115 shares were traded during trading, an increase of 1% from the average session volume of 31,851 shares. The stock had previously closed at $5.30.
Ono Pharmaceutical Trading Down 2.5%
The business has a 50-day moving average price of $4.99 and a 200-day moving average price of $5.02.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
